TrialBMC musculoskeletal disorders2011

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.

Rieke Alten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.